In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

MorphoSys to develop HuCAL antibodies for Centocor

Executive Summary

Monoclonal antibody developer MorphoSys AG will collaborate for five years with Johnson & Johnson's antibody division Centocor, using its HuCAL technology to raise optimized, fully human MAbs against Centocor disease targets.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register